Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23653399 | 0.90 | EGFR (0.57) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL16071706 | 0.85 | FGFR4 (0.83) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL16137318 | 0.83 | FGFR4 (0.79) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL16134052 | 0.81 | FGFR4 (0.76) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL16071407 | 0.79 | FGFR4 (0.73) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL23653276 | 0.79 | EGFR (0.44) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL16137324 | 0.78 | FGFR4 (0.79) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16071541 | 0.77 | FGFR4 (0.67) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16072036 | 0.77 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16071424 | 0.77 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR1 1733/4885FGFR2 879/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | FGFR4 1220/4885FGFR1 1156/4885FGFR2 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.